Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx Generic Diltiazem Will Launch After Hoechst Patent Suit Settlement

Executive Summary

Andrx will launch a reformulated once-daily diltiazem product following the resolution of a patent suit with Cardizem CD manufacturer Hoechst Marion Roussel.

You may also be interested in...



Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic

Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.

Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic

Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.

Purepac Challenges Andrx Cardia XT Exclusivity On Reformulation Grounds

A first-to-file ANDA applicant should lose its eligibility for 180-day exclusivity if it makes major changes to the application at a later date, Purepac asserts in a petition to FDA requesting that Andrx be stripped of its exclusivity for generic sustained-release diltiazem, equivalent to Hoechst Marion Roussel's Cardizem CD.

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel